flotetuzumab

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 500 ng/kg/day by continuous infusion over 7 days for each cycle (max)

Adverse effects

Mechanism of action

* CD123 is also expressed on monocytes, B cells, megakaryocytes, & plasmacytoid dendritic cells, & in smaller amounts on normal hematopoietic stem cells & hematopoietic progenitors

* CD123 has been detected >90% of blasts in patients with AML

More general terms

References

  1. O'Neil A CD123-Targeted Flotetuzumab Induces Some CRs in AML. DART molecule aimed at receptor expressed on most myeloid blast and leukemic stem cells. MedPage Today Oct 11, 2017 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/68470